Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?

Tempus will use its "Lens" data analytics platform to analyze and restructure genomic data from the the Abrams Research Center.

TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM’s main bet is now on AI for ...

In addition to raising doubts about Tempus AI's financial reporting, the critical report that Spruce Point issued last week questioned the nature of the company's collaboration with AstraZeneca.

The investigation concerns whether Tempus and certain of its officers ... partnerships and deal announcement[s] with AstraZeneca and Pathos AI merit scrutiny.” On this news, Tempus’ stock ...

Tempus AI responded that the report was "riddled with hypotheticals and inaccuracies and fails to address Tempus’ history of ...

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.